Evidence for long-term efficacy and safety of gene therapy for Wiskott-Aldrich syndrome in preclinical models

DOI: 10.1038/mt.2009.31
Molecular Therapy, 2009, 17, 1073-82.

#	Paper	IF	Citations
73	Ten years of gene therapy for primary immune deficiencies. *Hematology American Society of Hematology Education Program*, **2009**, 682-9	3.1	70
72	Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. *Molecular Therapy*, **2009**, 17, 1919-28	11.7	296
71	Recent advances in understanding the pathophysiology of Wiskott-Aldrich syndrome. *Blood*, **2009**, 113, 6288-95	2.2	184
70	Update on gene therapy for adenosine deaminase-deficient severe combined immunodeficiency. *Current Opinion in Allergy and Clinical Immunology*, **2010**, 10, 551-6	3.3	46
69	X-linked thrombocytopenia (XLT) due to WAS mutations: clinical characteristics, long-term outcome, and treatment options. *Blood*, **2010**, 115, 3231-8	2.2	146
68	Lentiviral vectors in gene therapy: their current status and future potential. *Archivum Immunologiae Et Therapiae Experimentalis*, **2010**, 58, 107-19	4	185
67	The Wiskott-Aldrich Syndrome: The Actin Cytoskeleton and Immune Cell Function. *Disease Markers*, **2010**, 29, 157-175	3.2	76
66	The Wiskott-Aldrich syndrome protein regulates CTL cytotoxicity and is required for efficient killing of B cell lymphoma targets. *Journal of Leukocyte Biology*, **2010**, 88, 1031-40	6.5	47
65	Gene therapy of MPL deficiency: challenging balance between leukemia and pancytopenia. *Molecular Therapy*, **2010**, 18, 343-52	11.7	25
64	Gene Therapy for Primary Immunodeficiencies. **2010**, 213-231		
63	Gene therapy for adenosine deaminase deficiency. *Immunology and Allergy Clinics of North America*, **2010**, 30, 249-60	3.3	11
62	Gene therapy for primary immunodeficiencies. *Immunology and Allergy Clinics of North America*, **2010**, 30, 237-48	3.3	8
61	Revertant T lymphocytes in a patient with Wiskott-Aldrich syndrome: analysis of function and distribution in lymphoid organs. *Journal of Allergy and Clinical Immunology*, **2010**, 125, 439-448.e8	11.5	28
60	Large-scale manufacture and characterization of a lentiviral vector produced for clinical ex vivo gene therapy application. *Human Gene Therapy*, **2011**, 22, 343-56	4.8	138
59	Development of novel efficient SIN vectors with improved safety features for Wiskott-Aldrich syndrome stem cell based gene therapy. *Molecular Pharmaceutics*, **2011**, 8, 1525-37	5.6	57
58	Introduction to gene therapy: a clinical aftermath. *Methods in Molecular Biology*, **2011**, 737, 27-44	1.4	10
57	Gene therapy for primary immunodeficiencies. *Hematology/Oncology Clinics of North America*, **2011**, 25, 89-100	3.1	7

56	Lentiviral-mediated gene therapy leads to improvement of B-cell functionality in a murine model of Wiskott-Aldrich syndrome. *Journal of Allergy and Clinical Immunology*, **2011**, 127, 1376-84.e5	11.5	32
55	Clinical spectrum, pathophysiology and treatment of the Wiskott-Aldrich syndrome. *Current Opinion in Hematology*, **2011**, 18, 42-8	3.3	71
54	Gene therapy for the Wiskott-Aldrich syndrome. *Current Opinion in Allergy and Clinical Immunology*, **2011**, 11, 545-50	3.3	34
53	Gene therapy for primary immunodeficiency. *Current Opinion in Pediatrics*, **2011**, 23, 659-66	3.2	18
52	Autoimmunity in wiskott-Aldrich syndrome: an unsolved enigma. *Frontiers in Immunology*, **2012**, 3, 209	8.4	93
51	Foamy virus vector-mediated gene correction of a mouse model of Wiskott-Aldrich syndrome. *Molecular Therapy*, **2012**, 20, 1270-9	11.7	21
50	Dendritic cell functional improvement in a preclinical model of lentiviral-mediated gene therapy for Wiskott-Aldrich syndrome. *Gene Therapy*, **2012**, 19, 1150-8	4	7
49	Ubiquitous high-level gene expression in hematopoietic lineages provides effective lentiviral gene therapy of murine Wiskott-Aldrich syndrome. *Blood*, **2012**, 119, 4395-407	2.2	42
48	B cell-intrinsic deficiency of the Wiskott-Aldrich syndrome protein (WASp) causes severe abnormalities of the peripheral B-cell compartment in mice. *Blood*, **2012**, 119, 2819-28	2.2	87
47	A novel lentiviral vector targets gene transfer into human hematopoietic stem cells in marrow from patients with bone marrow failure syndrome and in vivo in humanized mice. *Blood*, **2012**, 119, 1139-50	2.2	36
46	Lentiviral vectors and cardiovascular diseases: a genetic tool for manipulating cardiomyocyte differentiation and function. *Gene Therapy*, **2012**, 19, 642-8	4	21
45	Gene therapy for primary immunodeficiencies: Part 2. *Current Opinion in Immunology*, **2012**, 24, 585-91	7.8	51
44	Comparison of insulators and promoters for expression of the Wiskott-Aldrich syndrome protein using lentiviral vectors. *Human Gene Therapy Clinical Development*, **2013**, 24, 77-85	3.2	16
43	Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. *Science*, **2013**, 341, 1233151	33.3	755
42	Current progress on gene therapy for primary immunodeficiencies. *Gene Therapy*, **2013**, 20, 963-9	4	28
41	Gene therapy on the move. *EMBO Molecular Medicine*, **2013**, 5, 1642-61	12	187
40	Wiskott-Aldrich syndrome protein-deficient hematopoietic cells can be efficiently mobilized by granulocyte colony-stimulating factor. *Haematologica*, **2013**, 98, 1300-8	6.6	7
39	Hematopoietic stem cell gene therapy:assessing the relevance of preclinical models. *Seminars in Hematology*, **2013**, 50, 101-30	4	16

38	Wiskott-Aldrich syndrome: a comprehensive review. *Annals of the New York Academy of Sciences*, **2013**, 1285, 26-43	6.5	201
37	Understanding lentiviral vector chromatin targeting: working to reduce insertional mutagenic potential for gene therapy. *Gene Therapy*, **2013**, 20, 581-8	4	34
36	Two cases of Wiskott-Aldrich syndrome in neonates due to gene mutations. *Fetal and Pediatric Pathology*, **2013**, 32, 312-5	1.7	
35	Preclinical safety and efficacy of human CD34(+) cells transduced with lentiviral vector for the treatment of Wiskott-Aldrich syndrome. *Molecular Therapy*, **2013**, 21, 175-84	11.7	63
34	Development of gene therapy for blood disorders: an update. *Blood*, **2013**, 122, 1556-64	2.2	37
33	Gene Therapy of Genetic Diseases of Blood Cells. **2013**,		
32	[Current status and future prospects of stem cell gene therapy for primary immunodeficiency]. *Japanese Journal of Clinical Immunology*, **2013**, 36, 148-55		
31	Ecological Models for Gene Therapy. II. Niche Construction, Nongenetic Inheritance, and Ecosystem Perturbations. *Biological Theory*, **2014**, 9, 414-422	1.7	1
30	Gene transfer into hematopoietic stem cells as treatment for primary immunodeficiency diseases. *International Journal of Hematology*, **2014**, 99, 383-92	2.3	19
29	Concise review: lessons learned from clinical trials of gene therapy in monogenic immunodeficiency diseases. *Stem Cells Translational Medicine*, **2014**, 3, 636-42	6.9	41
28	Gene therapy for inherited immunodeficiency. *Expert Opinion on Biological Therapy*, **2014**, 14, 789-98	5.4	39
27	Gene therapy for monogenic disorders of the bone marrow. *British Journal of Haematology*, **2015**, 171, 155-170	4.5	27
26	RETRACTED: Novel and safer self-inactivating vectors for gene therapy of Wiskott-Aldrich Syndrome. *Current Gene Therapy*, **2015**, 15, 245 - 254	4.3	4
25	Dendritic cell-based vaccination with lentiviral vectors encoding ubiquitinated hepatitis B core antigen enhances hepatitis B virus-specific immune responses in vivo. *Acta Biochimica Et Biophysica Sinica*, **2015**, 47, 870-9	2.8	7
24	Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome. *JAMA - Journal of the American Medical Association*, **2015**, 313, 1550-63	27.4	245
23	Clinical applications of gene therapy for primary immunodeficiencies. *Human Gene Therapy*, **2015**, 26, 210-9	4.8	65
22	Lentivirus technologies for modulation of the immune system. *Current Opinion in Pharmacology*, **2015**, 24, 119-27	5.1	11
21	Lentiviral Vector Gene Therapy Protects XCGD Mice From Acute Staphylococcus aureus Pneumonia and Inflammatory Response. *Molecular Therapy*, **2016**, 24, 1873-1880	11.7	7

20	Lentiviral Engineered Fibroblasts Expressing Codon-Optimized COL7A1 Restore Anchoring Fibrils in RDEB. *Journal of Investigative Dermatology*, **2016**, 136, 284-92	4.3	34
19	Safe and Effective Gene Therapy for Murine Wiskott-Aldrich Syndrome Using an Insulated Lentiviral Vector. *Molecular Therapy - Methods and Clinical Development*, **2017**, 4, 1-16	6.4	9
18	New frontiers in the therapy of primary immunodeficiency: From gene addition to gene editing. *Journal of Allergy and Clinical Immunology*, **2017**, 139, 726-732	11.5	28
17	Gene Therapy Approaches to Immunodeficiency. *Hematology/Oncology Clinics of North America*, **2017**, 31, 823-834	3.1	6
16	Efficacy of lentivirus-mediated gene therapy in an Omenn syndrome recombination-activating gene 2 mouse model is not hindered by inflammation and immune dysregulation. *Journal of Allergy and Clinical Immunology*, **2018**, 142, 928-941.e8	11.5	16
15	Hematopoietic stem cell gene therapy for the cure of blood diseases: primary immunodeficiencies. *Rendiconti Lincei*, **2018**, 29, 755-764	1.7	2
14	Gene Therapy for Primary Immunodeficiencies. **2018**, 413-431		
13	Biosafety Studies of a Clinically Applicable Lentiviral Vector for the Gene Therapy of Artemis-SCID. *Molecular Therapy - Methods and Clinical Development*, **2019**, 15, 232-245	6.4	9
12	Lentiviral haemopoietic stem/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1/2 clinical study. *Lancet Haematology,the*, **2019**, 6, e239-e253	14.6	95
11	Transcriptional Targeting and MicroRNA Regulation of Lentiviral Vectors. *Molecular Therapy - Methods and Clinical Development*, **2019**, 12, 223-232	6.4	11
10	Advances in the gene therapy of monogenic blood cell diseases. *Clinical Genetics*, **2020**, 97, 89-102	4	9
9	Mouse models in hematopoietic stem cell gene therapy and genome editing. *Biochemical Pharmacology*, **2020**, 174, 113692	6	4
8	Gene therapy for Wiskott-Aldrich syndrome: History, new vectors, future directions. *Journal of Allergy and Clinical Immunology*, **2020**, 146, 262-265	11.5	11
7	Autoimmunity in Wiskott-Aldrich Syndrome: Updated Perspectives. *The Application of Clinical Genetics*, **2021**, 14, 363-388	3.1	1
6	Gene Therapy for Primary Immunodeficiency. *HemaSphere*, **2021**, 5, e509	0.3	5
5	More than just infections: an update on primary immune deficiencies. *Current Opinion in Pediatrics*, **2010**, 22, 647-54	3.2	5
4	Gene therapy. **2013**, 1054-1065		
3	Gene therapy goes the distance in Wiskott-Aldrich syndrome.. *Nature Medicine*, **2022**,	50.5	0

2	Wiskott-Aldrich syndrome: Oral findings and microbiota in children and review of the literature.. *Clinical and Experimental Dental Research*, **2022**, 8, 28-36	1.9	2
1	Genome Editing With TALEN, CRISPR-Cas9 and CRISPR-Cas12a in Combination With AAV6 Homology Donor Restores T Cell Function for XLP. *Frontiers in Genome Editing*, **2022**, 4,	2.5	1